Food-based natural products for cancer management

Is the whole greater than the sum of the parts?

Suleman S. Hussain, Addanki P Kumar, Rita Ghosh

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

The rise in cancer incidence and mortality in developing countries together with the human and financial cost of current cancer therapy mandates a closer look at alternative ways to overcome this burgeoning global healthcare problem. Epidemiological evidence for the association between cancer and diet and the long latency of most cancer progression have led to active exploration of whole and isolated natural chemicals from different naturally occurring substances in various preclinical and clinical settings. In general the lack of systemic toxicities of most ‘whole’ and ‘isolated’ natural compounds, their potential to reduce toxic doses and potential to delay the development of drug-resistance makes them promising candidates for cancer management. This review article examines the suggested molecular mechanisms affected by these substances focusing to a large extent on prostate cancer and deliberates on the disparate results obtained from cell culture, preclinical and clinical studies in an effort to highlight the use of whole extracts and isolated constituents for intervention. As such these studies underscore the importance of factors such as treatment duration, bioavailability, route of administration, selection criteria, standardized formulation and clinical end points in clinical trial design with both entities. Overall lack of parallel comparison studies between the whole natural products and their isolated compounds limits decisive conclusions regarding the superior utility of one over the other. We suggest the critical need for rigorous comparative research to identify which one of the two or both entities from nature would be best qualified to take on the mantle of cancer management.

Original languageEnglish (US)
Pages (from-to)233-246
Number of pages14
JournalSeminars in Cancer Biology
Volume40_41
DOIs
StatePublished - Oct 1 2016

Fingerprint

Biological Products
Food
Neoplasms
Poisons
Drug Resistance
Patient Selection
Biological Availability
Developing Countries
Prostatic Neoplasms
Cell Culture Techniques
Clinical Trials
Diet
Delivery of Health Care
Costs and Cost Analysis
Mortality
Incidence
Research

Keywords

  • Active compounds
  • Adjuvants
  • Cancer prevention
  • Cancer therapy
  • Food-based extracts

ASJC Scopus subject areas

  • Cancer Research

Cite this

Food-based natural products for cancer management : Is the whole greater than the sum of the parts? / Hussain, Suleman S.; Kumar, Addanki P; Ghosh, Rita.

In: Seminars in Cancer Biology, Vol. 40_41, 01.10.2016, p. 233-246.

Research output: Contribution to journalReview article

@article{aa57601c455645efb5f3f550f8eba2f5,
title = "Food-based natural products for cancer management: Is the whole greater than the sum of the parts?",
abstract = "The rise in cancer incidence and mortality in developing countries together with the human and financial cost of current cancer therapy mandates a closer look at alternative ways to overcome this burgeoning global healthcare problem. Epidemiological evidence for the association between cancer and diet and the long latency of most cancer progression have led to active exploration of whole and isolated natural chemicals from different naturally occurring substances in various preclinical and clinical settings. In general the lack of systemic toxicities of most ‘whole’ and ‘isolated’ natural compounds, their potential to reduce toxic doses and potential to delay the development of drug-resistance makes them promising candidates for cancer management. This review article examines the suggested molecular mechanisms affected by these substances focusing to a large extent on prostate cancer and deliberates on the disparate results obtained from cell culture, preclinical and clinical studies in an effort to highlight the use of whole extracts and isolated constituents for intervention. As such these studies underscore the importance of factors such as treatment duration, bioavailability, route of administration, selection criteria, standardized formulation and clinical end points in clinical trial design with both entities. Overall lack of parallel comparison studies between the whole natural products and their isolated compounds limits decisive conclusions regarding the superior utility of one over the other. We suggest the critical need for rigorous comparative research to identify which one of the two or both entities from nature would be best qualified to take on the mantle of cancer management.",
keywords = "Active compounds, Adjuvants, Cancer prevention, Cancer therapy, Food-based extracts",
author = "Hussain, {Suleman S.} and Kumar, {Addanki P} and Rita Ghosh",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.semcancer.2016.06.002",
language = "English (US)",
volume = "40_41",
pages = "233--246",
journal = "Seminars in Cancer Biology",
issn = "1044-579X",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Food-based natural products for cancer management

T2 - Is the whole greater than the sum of the parts?

AU - Hussain, Suleman S.

AU - Kumar, Addanki P

AU - Ghosh, Rita

PY - 2016/10/1

Y1 - 2016/10/1

N2 - The rise in cancer incidence and mortality in developing countries together with the human and financial cost of current cancer therapy mandates a closer look at alternative ways to overcome this burgeoning global healthcare problem. Epidemiological evidence for the association between cancer and diet and the long latency of most cancer progression have led to active exploration of whole and isolated natural chemicals from different naturally occurring substances in various preclinical and clinical settings. In general the lack of systemic toxicities of most ‘whole’ and ‘isolated’ natural compounds, their potential to reduce toxic doses and potential to delay the development of drug-resistance makes them promising candidates for cancer management. This review article examines the suggested molecular mechanisms affected by these substances focusing to a large extent on prostate cancer and deliberates on the disparate results obtained from cell culture, preclinical and clinical studies in an effort to highlight the use of whole extracts and isolated constituents for intervention. As such these studies underscore the importance of factors such as treatment duration, bioavailability, route of administration, selection criteria, standardized formulation and clinical end points in clinical trial design with both entities. Overall lack of parallel comparison studies between the whole natural products and their isolated compounds limits decisive conclusions regarding the superior utility of one over the other. We suggest the critical need for rigorous comparative research to identify which one of the two or both entities from nature would be best qualified to take on the mantle of cancer management.

AB - The rise in cancer incidence and mortality in developing countries together with the human and financial cost of current cancer therapy mandates a closer look at alternative ways to overcome this burgeoning global healthcare problem. Epidemiological evidence for the association between cancer and diet and the long latency of most cancer progression have led to active exploration of whole and isolated natural chemicals from different naturally occurring substances in various preclinical and clinical settings. In general the lack of systemic toxicities of most ‘whole’ and ‘isolated’ natural compounds, their potential to reduce toxic doses and potential to delay the development of drug-resistance makes them promising candidates for cancer management. This review article examines the suggested molecular mechanisms affected by these substances focusing to a large extent on prostate cancer and deliberates on the disparate results obtained from cell culture, preclinical and clinical studies in an effort to highlight the use of whole extracts and isolated constituents for intervention. As such these studies underscore the importance of factors such as treatment duration, bioavailability, route of administration, selection criteria, standardized formulation and clinical end points in clinical trial design with both entities. Overall lack of parallel comparison studies between the whole natural products and their isolated compounds limits decisive conclusions regarding the superior utility of one over the other. We suggest the critical need for rigorous comparative research to identify which one of the two or both entities from nature would be best qualified to take on the mantle of cancer management.

KW - Active compounds

KW - Adjuvants

KW - Cancer prevention

KW - Cancer therapy

KW - Food-based extracts

UR - http://www.scopus.com/inward/record.url?scp=84992217960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992217960&partnerID=8YFLogxK

U2 - 10.1016/j.semcancer.2016.06.002

DO - 10.1016/j.semcancer.2016.06.002

M3 - Review article

VL - 40_41

SP - 233

EP - 246

JO - Seminars in Cancer Biology

JF - Seminars in Cancer Biology

SN - 1044-579X

ER -